- $420.96m
- $132.77m
- $9.68m
Eli Lilly falls after rival Alzheimer's drug gets full approval with warning
Board Of Co Increased Size Of Board & Appointed William H. Dunn, Jr., M.D. To Serve As Director Of Co, Effective Immediately
Brief: Prothena Q1 collaboration revenue USD 2.119 million
Prothena Corporation PLC reports results for the quarter ended in March - Earnings Summary
Prothena Corporation PLC expected to post a loss of 94 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Tupperware, Netflix, Copper miners
U.S. STOCKS ON THE MOVE-Groupon, Hecla Mining, Harley-Davidson
Prothena up on pact with Walgreens for Alzheimer's drug trial
Brief: Walgreens And Prothena Partner To Increase Access And Enrollment In Alzheimer's Disease Clinical Trial
Brief: Prothena To Highlight Next Generation Treatments For Alzheimer’S And Parkinson’S Disease At The Ad/Pd 2023 Meeting
Brief: Prothena Corporation PLC Does Not Hold Cash Deposits Or Securities At Silicon Valley Bank
Qtrly Diluted Net Income Per Ordinary Share $0.12
Brief: Prothena Reports Q4 Revenue $49.923 Million
Prothena Corporation PLC reports results for the quarter ended in December - Earnings Summary
Prothena Corporation PLC expected to post a loss of 47 cents a share - Earnings Preview
Prothena Corporation PLC expected to post a loss of 47 cents a share - Earnings Preview
Brief: Prothena Reports Topline Early-Stage Trial Results Of Alzheimer’s Disease Treatment
Eli Lilly rises as rival Biogen's Alzheimer's drug gets FDA nod
U.S. STOCKS ON THE MOVE-Trip.com, Verizon Communications, Netflix